Initially, the first targeted therapies using TKIs for NSCLC were administered to patients with a mutated EGFR, specifically in advanced and metastatic NS-NSCLC with an actionable L858R or del 19 EGFR mutation or a resistant T790M EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.